One is wrong for multi-dose peptide vials and one is wrong for peptides entirely
These are all the conditions listed in the patent: Conditions and Disorders: Stress-Related Diseases & Disorders Gastrointestinal Conditions Ulcers in any part of the gastrointestinal tract General anti-inflammatory activity Gastrointestinal inflammatory diseases Crohns disease Acute pancreatitis Organoprotective Needs Diseases, conditions, or disorders requiring organoprotective activity Viral Infections Hepatitis A Herpes strains Influenza A Arthropod-borne (ARBO) viruses, including: Tick-borne encephalitis West Nile fever Dengue (types 1-4) Cytomegalovirus (CMV) Lymphocytic choriomeningitis (LCM) virus Feline leukemia virus Oncology & Tumors Melanoma and related tumors Tissue & Wound Healing Accelerated healing of wounds, burns, and bone fractures Regeneration of ruptured nerve linkages Achilles tendon and muscle repair Spinal cord injury recovery Nitric Oxide (NO)-Related Disorders Hypertension Hypotension Anaphylaxis Circulatory and septic shock Thrombocyte aggregation Neurological & Autoimmune Disorders Multiple sclerosis Myasthenia gravis Lupus erythematosus Neuropathy Somatosensory nerve dysfunction Asthma Rhinitis Pemphigus Eczema Neurochemical & Substance-Related Disorders Catecholaminergic dysfunction Schizophrenia Withdrawal effects from amphetamines, drugs, and alcohol Corticosteroid & NSAID-Related Disorders Ophthalmological Conditions Squamous degeneration of the macula Vascular & Circulatory Needs Conditions requiring rapid reorganization of blood supply Animal Health & Reproductive Enhancement Weight gain in animals Increased sperm stability in storage (in animals) Liver & Pancreatic Conditions Hepatic and pancreatic lesions While this list seems impressive, BPC-157 would have a much easier time coming to market if one disease state was focused on and pushed through the regulatory process
Aim the needle tip at the inside wall of the vial, not directly onto the powder cake
More human studies are necessary to support the existing data
Subcutaneous injection into any fatty tissue (abdomen, thigh, arm) allows the peptides to enter systemic circulation
Single nucleotide variations (polymorphisms) in the sequence of genes can modify gene expression level and the stability and activity of the synthesized proteins
